Skip to main content
Fig. 5 | Biomaterials Research

Fig. 5

From: Reduced restenosis and enhanced re-endothelialization of functional biodegradable vascular scaffolds by everolimus and magnesium hydroxide

Fig. 5

Genetic evaluation of HCAECs to confirm endothelial cell protection effects of the BVS/EVL/mMH. (A) Schematic illustration of proposed mechanism of the EVL and mMH effect on endothelial cell. Gene expression levels of (B) PI3K-AKT-mTOR pathway-, (C) apoptosis-, (D) Mg ion channel-, and (E) Angiogenesis-related markers on HCAECs. *p < 0.05, **p < 0.01, and ***p < 0.001 indicate statistically significant differences, respectively. PI3K: phosphoinositide-3-kinase; mTOR: mammalian target of rapamycin; S6K1: ribosomal protein S6 kinase beta-1; STAT3: signal transducer and activator of transcription 3; BCL-2: B-cell lymphoma 2; BAX: BCL-2 associated X; BAK: BCL-2 homologous antagonist killer; MRS2: mitochondrial RNA splicing protein 2; TRPM7: transient receptor potential cation channel, subfamily M, member 7; CD31: cluster of differentiation 31 (PECAM-1); VEGF: vascular endothelial growth factor

Back to article page